Skip to main content
SpringerLink
Log in

Adjuvant Therapy for High-Risk Renal Cell Carcinoma

  • Chapter
  • First Online:
Diagnosis and Surgical Management of Renal Tumors

  • 735 Accesses

Abstract

The current standard of care for the treatment of patients with high-risk localized or locally advanced renal cell carcinoma is surgical resection alone. Due to the high risk of disease progression and cancer-related death among these patients, there has been considerable interest in exploring adjuvant therapies for use following surgical extirpation. Unfortunately efforts aimed at studying a range of postoperative therapies including cytokine immunotherapy, cancer vaccines, hormonal therapy, and radiation have failed to show a clinical benefit. Additionally, more recent data from two large clinical trials failed to show a survival advantage with the use of adjuvant tyrosine kinase inhibitors , albeit one of these trials did show a benefit in terms of disease-free survival. A number of trials evaluating other adjuvant treatments for high-risk RCC are currently underway including studies evaluating immune checkpoint inhibitors. In this chapter we summarize the literature on adjuvant therapy for high-risk localized renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21.

    Article  Google Scholar 

  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359–86.

    Article  Google Scholar 

  3. Kane CJ, Mallin K, Rithcey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113:78–83.

    Article  Google Scholar 

  4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radial or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–52.

    Article  Google Scholar 

  5. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24(19):3101–6.

    Article  Google Scholar 

  6. Pantuck AJ, Zisman A, Dorey F, Caho DH, Han KR, Said J. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169(9):2076–83.

    Article  Google Scholar 

  7. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49:324–31.

    Article  Google Scholar 

  8. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51.

    Article  Google Scholar 

  9. Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, et al. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol. 2017;71(4):665–73.

    Article  Google Scholar 

  10. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:55–7.

    Google Scholar 

  11. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.

    Article  CAS  Google Scholar 

  12. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19(2):425–31.

    Article  CAS  Google Scholar 

  13. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma. J Clin Oncol. 2003;21(7):1214–22.

    Article  CAS  Google Scholar 

  14. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al. Adjuvant treatment with interluekin2 and interferon alpha based chemoimmunotherapy in renal cell carcinoma post tumor nephrectomy: results of a prospectively randomized trial of the German Cooperative Renal Cell Carcinoma Chemoimmunotherapy Group. Br J Cancer. 2005;92(5):843–6.

    Article  CAS  Google Scholar 

  15. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Farvaro D, et al. Adjuvant immunotherapy treatment of renal cell carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: a five-year result of a prospective randomized study. Cancer. 1996;77(12):2560–6.

    Article  CAS  Google Scholar 

  16. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrewski G, et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal cell carcinoma after radial nephrectomy: phase III, randomized controlled trial. Lancet. 2004;363(9409):594–9.

    Article  CAS  Google Scholar 

  17. Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009;55:1333–44.

    Article  Google Scholar 

  18. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open-label, randomized phase III trial. Lancet. 2008;372(9633):145–54.

    Article  CAS  Google Scholar 

  19. Scherr AJ, Lima JP, Sasse EC, Lima CS, Sasse AD. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer. 2011;11(115):1–7.

    Google Scholar 

  20. Chamie K, Donin NM, Klopfer P, Bevan P, Fall B, Wilhelm O, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3(7):913–20.

    Article  Google Scholar 

  21. Karr JP, Pontes JP, Schneider S, Sandberg JP, Murphy JP. Clinical aspect of steroid hormone receptors in human renal cell carcinoma. J Surg Oncol. 1983;23(2):117–24.

    Article  CAS  Google Scholar 

  22. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5 year prospective randomized study. J Urol. 1987;138(6):1379–81.

    Article  CAS  Google Scholar 

  23. Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol. 1982;138(6):1379–81.

    Google Scholar 

  24. Campbell SP, Song DY, Pierorazio PM, Allaf ME, Gorin MA. Stereotactic ablative radiotherapy for the treatment of clinically localized renal cell carcinoma. J Oncol. 2015;2015:547143.

    Article  Google Scholar 

  25. Kjaer M, Iversen P, Hvidt V, Bruun W, Skaarup P, Hansen JB, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma, a study by the Copenhagen renal cancer study group. Scand J Urol Nephrol. 1987;21(4):285–9.

    Article  CAS  Google Scholar 

  26. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

    Article  CAS  Google Scholar 

  27. Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016;11:23–36.

    Article  Google Scholar 

  28. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant Sunitinib or Sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomized, phase 3 trial. Lancet. 2016;387(10032):2008–16.

    Article  CAS  Google Scholar 

  29. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54.

    Article  CAS  Google Scholar 

  30. Porta C, Chiellino S. ASSURE vs. STRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med. 2016;4:1–5.

    Article  Google Scholar 

  31. Gyawal B, Ando Y. Adjuvant sunitinib for high risk resected renal cell carcinoma: a meta-analysis of ASSURE and STRAC trials. Ann Oncol. 2017;28(4):898–9.

    Google Scholar 

  32. Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol. 2013;24(7):1730–40.

    Article  CAS  Google Scholar 

  33. Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, et al. Adjuvant treatment for high risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 2017;3(9):1249–52.

    Article  Google Scholar 

  34. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (PROTECT). J Clin Oncol. 2017;35(15_suppl):4507.

    Article  Google Scholar 

  35. Alme AK, Karir BS, Faltas BM, Drake CG. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: an overview. Urol Oncol. 2016;34(4):171–81.

    Article  CAS  Google Scholar 

  36. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    James L. Liu, Mohamad E. Allaf & Michael A. Gorin

Authors
  1. James L. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamad E. Allaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Gorin .

Editor information

Editors and Affiliations

  1. The James Buchanan Brady Urological, Institute and Department of Urology, Johns Hopkins University School of Medic, Baltimore, MD, USA

    Michael A. Gorin

  2. The James Buchanan Brady Urological, Institute and Department of Urology, Johns Hopkins University School of Medic, Baltimore, MD, USA

    Mohamad E. Allaf

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Liu, J.L., Allaf, M.E., Gorin, M.A. (2019). Adjuvant Therapy for High-Risk Renal Cell Carcinoma. In: Gorin, M., Allaf, M. (eds) Diagnosis and Surgical Management of Renal Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-92309-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92309-3_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92308-6

  • Online ISBN: 978-3-319-92309-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation